297 related articles for article (PubMed ID: 24204956)
21. MN1 overexpression with varying tumor grade is a promising predictor of survival of glioma patients.
Saini M; Jha AN; Tangri R; Qudratullah M; Ali S
Hum Mol Genet; 2021 Jan; 29(21):3532-3545. PubMed ID: 33105486
[TBL] [Abstract][Full Text] [Related]
22. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
23. Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma.
Lu G; Chang JT; Liu Z; Chen Y; Li M; Zhu JJ
Mol Neurobiol; 2016 Nov; 53(9):6511-6525. PubMed ID: 26614510
[TBL] [Abstract][Full Text] [Related]
24. Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas.
Coppola D; Balducci L; Chen DT; Loboda A; Nebozhyn M; Staller A; Fulp WJ; Dalton W; Yeatman T; Brem S
J Geriatr Oncol; 2014 Oct; 5(4):389-99. PubMed ID: 25220188
[TBL] [Abstract][Full Text] [Related]
25. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
[TBL] [Abstract][Full Text] [Related]
26. Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas.
Wang XB; Tian XY; Li Y; Li B; Li Z
J Neurooncol; 2012 Jan; 106(1):43-51. PubMed ID: 21725855
[TBL] [Abstract][Full Text] [Related]
27. Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.
Nejo T; Matsushita H; Karasaki T; Nomura M; Saito K; Tanaka S; Takayanagi S; Hana T; Takahashi S; Kitagawa Y; Koike T; Kobayashi Y; Nagae G; Yamamoto S; Ueda H; Tatsuno K; Narita Y; Nagane M; Ueki K; Nishikawa R; Aburatani H; Mukasa A; Saito N; Kakimi K
Cancer Immunol Res; 2019 Jul; 7(7):1148-1161. PubMed ID: 31088845
[TBL] [Abstract][Full Text] [Related]
28. High expression of RAB43 predicts poor prognosis and is associated with epithelial-mesenchymal transition in gliomas.
Han MZ; Huang B; Chen AJ; Zhang X; Xu R; Wang J; Li XG
Oncol Rep; 2017 Feb; 37(2):903-912. PubMed ID: 28075478
[TBL] [Abstract][Full Text] [Related]
29. High expression of forkhead box protein C2 is related to poor prognosis in human gliomas.
Wang YW; Yin CL; Zhang HY; Hao J; Yang YY; Liao H; Jiao BH
Asian Pac J Cancer Prev; 2014; 15(24):10621-5. PubMed ID: 25605149
[TBL] [Abstract][Full Text] [Related]
30. Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas.
Bockmayr M; Klauschen F; Maire CL; Rutkowski S; Westphal M; Lamszus K; Schüller U; Mohme M
Cancer Immunol Res; 2019 Sep; 7(9):1401-1411. PubMed ID: 31266783
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients.
Chen W; Yu Q; Chen B; Lu X; Li Q
Oncotarget; 2016 Aug; 7(33):53392-53413. PubMed ID: 27438144
[TBL] [Abstract][Full Text] [Related]
32. Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma.
Shee K; Chambers M; Hughes EG; Almiron DA; Deharvengt SJ; Green D; Lefferts JA; Andrew AS; Hickey WF; Tsongalis GJ
J Neurooncol; 2020 Jul; 148(3):473-480. PubMed ID: 32583303
[TBL] [Abstract][Full Text] [Related]
33. Computational analysis of the mesenchymal signature landscape in gliomas.
Celiku O; Tandle A; Chung JY; Hewitt SM; Camphausen K; Shankavaram U
BMC Med Genomics; 2017 Mar; 10(1):13. PubMed ID: 28279210
[TBL] [Abstract][Full Text] [Related]
34. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
35. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-13 receptor α2 is a novel marker and potential therapeutic target for human melanoma.
Okamoto H; Yoshimatsu Y; Tomizawa T; Kunita A; Takayama R; Morikawa T; Komura D; Takahashi K; Oshima T; Sato M; Komai M; Podyma-Inoue KA; Uchida H; Hamada H; Fujiu K; Ishikawa S; Fukayama M; Fukuhara T; Watabe T
Sci Rep; 2019 Feb; 9(1):1281. PubMed ID: 30718742
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value and their clinical implication of 89-gene signature in glioma.
Shahid M; Cho KM; Nguyen MN; Choi TG; Jo YH; Aryal SN; Yoo JY; Yun HR; Lee JW; Eun YG; Lee JS; Kang I; Ha J; Yoon HJ; Kim SY; Kim SS
Oncotarget; 2016 Aug; 7(32):51237-51250. PubMed ID: 27323413
[TBL] [Abstract][Full Text] [Related]
38. A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
J Neurooncol; 2013 Sep; 114(3):309-17. PubMed ID: 23817809
[TBL] [Abstract][Full Text] [Related]
39. Cell aging related genes can be used to characterize clinical prognoses and further stratify diffuse gliomas.
Yang Y; Chen X; Sun J; Chen S; Yang C; Ma Q; Yang J
Sci Rep; 2021 Sep; 11(1):19493. PubMed ID: 34593910
[TBL] [Abstract][Full Text] [Related]
40. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
Zeng J; Zhang XK; Chen HD; Zhong ZH; Wu QL; Lin SX
Oncotarget; 2016 Feb; 7(8):8944-55. PubMed ID: 26771840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
